Vertex Pharmaceuticals (VRTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to -$6.3 billion.
- Vertex Pharmaceuticals' Enterprise Value rose 364.01% to -$6.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.3 billion, marking a year-over-year increase of 364.01%. This contributed to the annual value of -$6.1 billion for FY2024, which is 4548.28% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its Enterprise Value stood at -$6.3 billion for Q3 2025, which was up 364.01% from -$6.4 billion recorded in Q2 2025.
- Vertex Pharmaceuticals' Enterprise Value's 5-year high stood at -$5.8 billion during Q2 2024, with a 5-year trough of -$11.9 billion in Q3 2023.
- In the last 5 years, Vertex Pharmaceuticals' Enterprise Value had a median value of -$7.5 billion in 2021 and averaged -$8.3 billion.
- In the last 5 years, Vertex Pharmaceuticals' Enterprise Value crashed by 6523.35% in 2021 and then soared by 4842.16% in 2024.
- Vertex Pharmaceuticals' Enterprise Value (Quarter) stood at -$7.5 billion in 2021, then crashed by 43.24% to -$10.8 billion in 2022, then decreased by 4.08% to -$11.2 billion in 2023, then skyrocketed by 45.48% to -$6.1 billion in 2024, then fell by 2.8% to -$6.3 billion in 2025.
- Its Enterprise Value stands at -$6.3 billion for Q3 2025, versus -$6.4 billion for Q2 2025 and -$6.2 billion for Q1 2025.